Global Chronic Gonadotropin Market Size By Type (Human Chronic Gonadotropin, Animal Chronic Gonadotropin), By Application (Hospital, Medical Centres), By Region, And Segment Forecasts, 2023 to 2032

The Global Chronic Gonadotropin Market was valued at USD 540 million in 2023 and is projected to reach USD 875 million by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. The market is primarily driven by the rising incidence of infertility in both men and women, increasing adoption of hormone therapy, and expanding awareness of assisted reproductive technologies (ART). Chronic gonadotropin, particularly human chorionic gonadotropin (hCG), is widely used in fertility treatments, weight management, and testosterone regulation therapies. As healthcare access improves globally and reproductive health garners more policy and public attention, the market is set for steady growth.

Drivers:

1. Rising Prevalence of Infertility:

Globally, lifestyle changes, late pregnancies, and hormonal imbalances have contributed to a significant increase in infertility rates. Chronic gonadotropin plays a critical role in ovulation induction and treatment of male hypogonadism, thereby boosting demand.

2. Growing Adoption of Assisted Reproductive Technologies (ART):

Increasing acceptance and availability of ART procedures, such as IVF and IUI, where hCG is essential for ovulation induction, are accelerating market expansion.

3. Expanding Applications Beyond Reproduction:

Beyond fertility treatment, chronic gonadotropin is increasingly used in testosterone therapy and weight loss management, further widening its market scope.

Restraints:

1. Potential Side Effects and Misuse:

Use of chronic gonadotropin, especially off-label for weight loss and performance enhancement, raises safety and ethical concerns. Side effects such as ovarian hyperstimulation syndrome (OHSS) may limit patient compliance.

2. Regulatory Constraints and Approval Hurdles:

Strict regulatory requirements for therapeutic hormones and delays in drug approvals can hinder product launches and market penetration, especially in emerging markets.

Opportunity:

1. Expanding Fertility Clinics in Emerging Economies:

The proliferation of fertility clinics in regions such as Asia-Pacific and Latin America, supported by favorable demographics and increasing healthcare investment, presents untapped growth potential.

2. Integration with Personalized Medicine:

Advancements in genomics and hormone monitoring enable more tailored fertility treatments, where targeted use of chronic gonadotropin is becoming increasingly prevalent.

Market by System Type Insights:

Based on system type, the Recombinant hCG segment accounted for the largest market share in 2023. This dominance is attributed to its high purity, consistent clinical outcomes, and reduced risk of allergic reactions compared to urinary-derived hCG. The urinary-derived hCG segment, though declining, still holds relevance in cost-sensitive markets and is expected to see steady usage.

Market by End-use Insights:

In 2023, the Fertility Clinics segment emerged as the largest end-use category, contributing over 60% of market revenue. This is driven by rising demand for fertility treatments globally and the growing prevalence of male and female reproductive health issues. The hospital segment also plays a crucial role, particularly for inpatient hormone therapy in hypogonadism and cancer-related treatments.

Market by Regional Insights:

North America held the largest share of the chronic gonadotropin market in 2023, owing to well-established healthcare infrastructure, advanced reproductive health technologies, and high awareness levels. Asia-Pacific is projected to grow at the fastest rate during the forecast period, supported by rising infertility rates, increasing ART procedures, and improving access to fertility care in countries such as India, China, and Japan.

Competitive Scenario:

Key players in the global chronic gonadotropin market include:

Merck & Co., Inc.

Ferring Pharmaceuticals

Fresenius Kabi AG

Sun Pharmaceutical Industries Ltd.

Bharat Serums and Vaccines Limited

IBSA Institut Biochimique SA

Aspen Pharmacare

Teva Pharmaceutical Industries Ltd.

These companies are focusing on strategic expansions, new product approvals, and partnerships with fertility clinics to enhance their market footprint.

Scope of Work – Global Chronic Gonadotropin Market

Key Market Developments:

2023: Merck announced expansion of its fertility product portfolio with digital fertility monitoring integration to optimize hCG administration timing.

2024: Ferring Pharmaceuticals launched a new high-dose recombinant hCG formulation targeting resistant anovulatory infertility cases.

2025: IBSA Institut Biochimique SA entered a strategic partnership with fertility networks across Southeast Asia to expand regional market access.

FAQs:

1) What is the current market size of the Global Chronic Gonadotropin Market?

The market was valued at USD 540 million in 2023.

2) What is the major growth driver of the Global Chronic Gonadotropin Market?

The major driver is the rising prevalence of infertility and increased adoption of assisted reproductive technologies.

3) Which is the largest region during the forecast period in the Global Chronic Gonadotropin Market?

North America is expected to remain the largest region, while Asia-Pacific is anticipated to experience the fastest growth.

4) Which segment accounted for the largest market share in Global Chronic Gonadotropin Market?

The Recombinant hCG segment led the market in 2023.

5) Who are the key market players in the Global Chronic Gonadotropin Market?

Key players include Merck, Ferring Pharmaceuticals, Fresenius Kabi, Sun Pharma, and IBSA.